Simulations Plus (NASDAQ:SLP) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Simulations Plus (NASDAQ:SLP - Get Free Report) released its quarterly earnings data on Tuesday. The technology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01), Zacks reports. The firm had revenue of $18.90 million for the quarter, compared to the consensus estimate of $18.80 million. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business's revenue for the quarter was up 30.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Simulations Plus updated its FY25 guidance to $1.07-$1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Trading Up 4.4 %

Shares of SLP traded up $1.29 on Tuesday, reaching $30.39. 523,489 shares of the company's stock were exchanged, compared to its average volume of 317,796. Simulations Plus has a 12 month low of $27.07 and a 12 month high of $51.22. The stock has a market capitalization of $610.38 million, a P/E ratio of 62.02 and a beta of 0.80. The business has a 50 day moving average price of $29.78 and a two-hundred day moving average price of $34.16.

Insiders Place Their Bets

In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $31.76, for a total transaction of $635,200.00. Following the transaction, the director now owns 3,442,584 shares of the company's stock, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 19.40% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on SLP. Stephens assumed coverage on shares of Simulations Plus in a research note on Friday, November 15th. They issued an "overweight" rating and a $39.00 target price on the stock. StockNews.com lowered Simulations Plus from a "hold" rating to a "sell" rating in a research note on Monday, November 4th. William Blair restated an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, November 6th. Finally, BTIG Research lowered their price target on Simulations Plus from $60.00 to $50.00 and set a "buy" rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $51.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.